论文部分内容阅读
目的观察更昔洛韦治疗小儿传染性单核细胞增多症的临床疗效。方法对92例传染性单核细胞增多症患儿随机分为2组,分别给予更昔洛韦和利巴韦林治疗,观察治疗组和对照组体温恢复正常,淋巴结缩小,肝脏缩小时间,异常淋巴细胞恢复至小于10%的时间和住院时间比较,并对以上各项临床指标进行分析。结果治疗组体温恢复正常,淋巴结缩小,肝脏缩小时间,异常淋巴细胞恢复至小于10%的时间和住院时间分别为3.20±1.30天,5.37±1.38天,4.68±1.02天,4.02±1.98天,4.59±2.06天和9.29±2.56,明显短于对照组的4.87±1.18天,6.32±1.93天,5.53±1.68天,5.98±1.99天,7.11±2.38天和11.32±2.32天,两组时间比较均有显著差异;治疗组总有效率88.5%,明显高于对照组的总有效率65%(P<0.01)。结论更昔洛韦治疗小儿传染性单核细胞增多症疗效高,可明显缩短体温恢复正常,淋巴结和肝脏缩小时间,异常淋巴细胞恢复至小于10%的时间和住院时间。
Objective To observe the clinical efficacy of ganciclovir in the treatment of childhood infectious mononucleosis. Methods Ninety-two children with infectious mononucleosis were randomly divided into 2 groups and treated with ganciclovir and ribavirin respectively. The body temperature returned to normal, lymph node reduction, liver shrinkage time and abnormality in the treatment group and the control group were observed Lymphocyte recovery to less than 10% of the time compared with hospital stay, and the above clinical indicators were analyzed. Results The body temperature returned to normal, lymph node reduction, liver shrinkage time and abnormal lymphocyte recovery to less than 10% were 3.20 ± 1.30 days, 5.37 ± 1.38 days, 4.68 ± 1.02 days, 4.02 ± 1.98 days and 4.59 ± 2.06 days and 9.29 ± 2.56, which were significantly shorter than those in the control group (4.87 ± 1.18 days, 6.32 ± 1.93 days, 5.53 ± 1.68 days, 5.98 ± 1.99 days, 7.11 ± 2.38 days and 11.32 ± 2.32 days, respectively) The total effective rate was 88.5% in the treatment group, which was significantly higher than 65% in the control group (P <0.01). Conclusion Ganciclovir treatment of children with infectious mononucleosis syndrome with high efficacy, can significantly shorten the body temperature returned to normal, lymph node and liver shrinking time, abnormal lymphocytes recovered to less than 10% of the time and hospital stay.